# External Competitive / New-Product / Workflow Radar — 2026-09-21T18:00:21Z

## Status / scope / evidence boundary

- Run status: **COMPLETE_FOCAL_ANALYSIS / FRESH_OWNER_INVENTORY / NO_MATERIAL_NOTIFICATION / 0_NEW_ISSUES**.
- Primary intelligence source this round was the public web outside Reese-max GitHub. GitHub was used for current owner scope, product truth, direction, duplicate/ownership checks and this durable report.
- Governing gate re-read: `docs/portfolio-audit/2026-09-14-issue-quality-v2.md`; rules blob SHA **`8167e10798071d2276addaff6b201c6b0e904a2a`**.
- Fresh connected-owner enumeration was paged to completion: **42 Reese-max-owned repositories / 41 unarchived**; page 2 was empty and `obsidian-vault` is archived/excluded. No historical inventory was used as the denominator.
- Fair cursor entering this round: **`Reese-max/clinical-scribe-worker`**, carried from `2026-09-21T155656Z-external-radar.md`.
- Focal default branch/head rechecked immediately before report write: **`main@4de4e7e9976f9f17619f0b9f4caaed2d5e23b2b5`** (`docs: record round 4 CI regression evidence`). The latest substantive product/security implementation baseline remains `88bb7469508e8732aaff6f21d048c8677823fc04`; later default-branch commits are audit documentation.
- Current Product Board direction remains **INVEST / SIMPLIFY**. NOW = repair the authenticated trust boundary (#6) and honest executing CI/provider evidence (#10). NEXT = only after those trust/release gates, continue already-bounded specialty validation (#4) and section repair/revision (#7). DO NOT = expand toward real clinical use, EHR actions, autonomous diagnosis/coding, a generic IAM platform, a new CI platform, or other clinical breadth.
- Current product boundary remains **competition prototype / synthetic and non-clinical research only**. Real patient data/PII and clinical use are outside the approved scope.
- Open implementation/research ownership remains active: #6 has PRs #15/#13/#8; #10 has PRs #14/#11; #4 has PRs #12/#5; #7 has PR #9. This radar did not rewrite or comment on those scopes.
- No Gemini/provider call, paid request, Cloudflare Access tenant, deployed Worker, browser/device, clinician/patient, EHR, PHI, production data, CI rerun, branch, merge, deployment, worker/GOAL, product source/config/secret/permission/settings mutation was performed. Source evidence is not represented as runtime evidence.

## Executive decision

**0 new Issues. 0 Issue/PR comments. 0 scope changes. 0 implementation authorizations.**

The strongest fresh-to-this-radar public-web signal is **Abridge's 2026-09-14 pre-bill review expansion**: the vendor is carrying source-grounded clinical context beyond note drafting into a downstream CDI/coding review step, comparing final coded diagnoses/DRG to supporting documentation and showing evidence behind discrepancies before claim submission. This is a meaningful category strategy signal, but it does **not** establish that `clinical-scribe-worker` should add coding, billing or revenue-cycle scope. The current product is synthetic/non-clinical, and its existing #4/#7 research already contains the smaller transferable primitives: source fidelity, candidate/review state, revision receipts and fail-closed support/unknown states.

Two additional external patterns reinforce rather than overturn existing direction:

1. **Dragon Copilot diagnosis-specificity suggestions (current capability; publication date not exposed on the support page, checked 2026-09-21)** pair every proposed diagnosis refinement with supporting rationale and require explicit accept/reject/ignore. The note is never changed automatically; EHR sync is an additional explicit step. This directly supports the existing `candidate -> evidence -> human decision -> canonical update` boundary rather than autonomous diagnosis mutation.
2. **The UK National Commission into the Regulation of AI in Healthcare (2026-09-10)** recommends proportionate, lifecycle-based, system-wide assurance and emphasizes human oversight and an expectation that people are informed. It is a recommendation package, not a new product-specific legal finding, and a cross-government response is still pending. For this repo it strengthens the sequencing argument for evidence/review before scope expansion; it does not create a present engineering defect.

The market signal therefore remains: **clinical-AI value is moving downstream from “generate a note” toward evidence-linked review and bounded decisions.** The smallest useful response here is not to add downstream clinical actions. It is to keep the current synthetic validation/revision work honest, source-linked and non-autonomous, while resolving #6/#10 first.

---

## Product → market category

| Product | Direct / adjacent market category | Current supported job |
|---|---|---|
| `clinical-scribe-worker` | ambient/clinical documentation prototype; synthetic note validation; review/repair research | synthetic transcript/profile → differential + source-constrained SOAP draft → explicit human review/evidence, with no real-patient or autonomous clinical authority |

## External Signals

### A. Direct competitor strategy — Abridge extends conversation provenance into pre-bill CDI/coding review

**CONFIRMED first-party release — event date 2026-09-14; checked 2026-09-21.**

Source: https://www.abridge.com/press-release/pre-bill-review-for-cdi-and-coding-teams

Abridge announced a pre-bill review capability for CDI, coding and revenue-cycle teams. The product compares final coded diagnoses and DRG against what the clinical documentation supports, and surfaces the evidence behind discrepancies while the claim is still reviewable before submission.

**User job solved:** downstream reviewers otherwise need to manually reconcile coded diagnoses/DRG with the chart and resolve unsupported or inconsistent coding after the fact.

**Concrete manual work reduced:** chart/code cross-checking, hunting for support, and retrospective discrepancy resolution.

**Transferable product pattern:** keep a generated/derived artifact connected to the source evidence used to justify it; surface discrepancies while the result is still a candidate/reviewable state.

**What not to copy:** billing, payer submission, CDI workspace, DRG engine, claims workflow, EHR integration or autonomous coding. None is within the approved synthetic/non-clinical scope and no local user/job evidence establishes their value here.

**Repository mapping:** the transferable primitive is already represented by #4 source/support validation and #7 candidate/revision receipts. Abridge's expansion raises confidence in those boundaries but does not establish a new root cause or grant implementation authority.

**Decision:** `STRATEGY_SIGNAL / DEDUP_TO_#4+#7 / NO_NEW_ISSUE`.

### B. Adjacent high-risk workflow — Dragon Copilot keeps diagnosis refinement as evidence-backed candidate action

**CONFIRMED_CURRENT first-party capability — page publication date not exposed; checked 2026-09-21.**

Source: https://support.microsoft.com/en-us/dragon-copilot/physicians/current/diagnosis-specificity-suggestions

Dragon Copilot can suggest a more specific diagnosis after note generation when it finds sufficient documented evidence. Each suggestion includes supporting rationale. The clinician can accept, reject/dismiss, or ignore it; the note is **never updated automatically**. In integrated experiences, updating the EHR requires a further explicit sync action.

**User job solved:** improve specificity without forcing the clinician to reconstruct the supporting evidence or surrender final control of the note.

**Concrete risk reduced:** a model suggestion is kept separate from canonical note mutation and from EHR synchronization.

**Transferable pattern:** `suggestion != note mutation != external-system write`. Supporting rationale belongs next to the candidate; no action should be inferred from model confidence alone.

**Current repo contrary evidence:** #7 already defines candidate section revisions, diff/review, stale-input handling, explicit Accept/Reject and revision receipts. The SOAP prompt also explicitly says the system produces draft/suggested directions and must not issue executable treatment orders. A new diagnosis-suggestion state machine would duplicate the existing bounded research rather than solve a distinct current failure.

**Decision:** `MUST-MATCH PRINCIPLE / DEDUP_TO_#7 / NO_SCOPE_CHANGE`.

### C. Policy / assurance signal — UK healthcare-AI recommendations move toward lifecycle assurance and human oversight

**CONFIRMED government recommendation — published 2026-09-10; checked 2026-09-21.**

Sources:
- https://www.gov.uk/government/news/independent-commission-led-by-nhs-doctors-sets-out-blueprint-to-accelerate-safe-ai-adoption-in-healthcare
- https://www.gov.uk/government/publications/national-commission-into-the-regulation-of-ai-in-healthcare-recommendations-for-a-future-regulatory-framework

The UK National Commission into the Regulation of AI in Healthcare recommends a more proportionate, lifecycle-based and system-wide assurance model. The accompanying government summary highlights public priorities including accuracy, human oversight and an expectation to be informed. A cross-government response will follow; these recommendations are not treated here as a final new statutory obligation for this product.

**Transferable pattern:** one pre-release quality score is not enough evidence for a changing clinical AI system. Intended use, version/release evidence and human oversight need to remain explicit over the lifecycle.

**Current repo mapping:** #4 already proposes versioned ValidationPacks with model/prompt/parser versions and per-pack promotion/block receipts. #10 already requires honest execution evidence. The signal therefore strengthens existing sequencing; it does not justify a regulatory/compliance subsystem.

**Decision:** `ASSURANCE_SIGNAL / EXISTING_DIRECTION_CONFIRMED / NO_NEW_ISSUE`.

### D. Representative deployment pattern — patient transparency/opt-out remains a separate operational layer

**CONFIRMED first-party government deployment examples; older than the preferred 30–90-day window but retained only as a representative slower-changing pattern.**

Sources:
- VA Orlando, 2026-01-27: https://www.va.gov/orlando-health-care/news-releases/orlando-va-health-care-system-to-implement-ambient-scribe-technology-to-enhance-veteran-care/
- VA Minneapolis, 2026-04-27: https://www.va.gov/minneapolis-health-care/stories/minneapolis-va-healthcare-system-introduces-new-ai-technology-to-improve-veterans-primary-care-experience/

VA deployment pages explicitly tell patients when ambient scribing is used, allow them to decline/opt out, and keep clinician review before documentation is saved.

This is **not** a current product requirement because `clinical-scribe-worker` does not have an approved real-patient workflow. It is retained only as future intended-use boundary evidence: if owner scope ever changes, consent/notice and clinician review are separate workflow contracts, not UI decoration.

**Decision:** `ADJACENT DEPLOYMENT PATTERN / DEFERRED UNTIL SCOPE CHANGE`.

---

## New Releases / recent strategy changes

| Date | Product / authority | Signal | Current decision |
|---|---|---|---|
| 2026-09-14 | Abridge | pre-bill review ties coded diagnoses/DRG discrepancies to supporting documentation before claim submission | meaningful strategy signal; reuse source-linked review principle, do not add billing scope |
| current; checked 2026-09-21 | Microsoft Dragon Copilot | diagnosis-specificity candidates include rationale; explicit accept/reject; no automatic note mutation; EHR sync separate | confirms #7 candidate/human-approval boundary |
| 2026-09-10 | UK National Commission / MHRA | lifecycle/system-wide assurance, human oversight, expectation to be informed | confirms validation/release sequencing; not a new implementation mandate |

No current pricing signal was used for prioritization. Vendor packaging or market scale is not treated as proof that a capability improves this product's supported workflow.

## Community Pain

No fresh community anecdote passed the bar for decision-grade evidence this round. Search did not yield a recent, directly relevant discussion stronger than the already-recorded clinician proofreading/editing concerns in prior clinical-scribe radars. No anecdote, vendor testimonial or synthetic persona count is promoted into prevalence, severity, ROI or implementation priority.

---

## Current repository / direction calibration

### Default-branch truth

Current focal HEAD remains `4de4e7e9976f9f17619f0b9f4caaed2d5e23b2b5`; the last substantive product/security baseline remains `88bb7469508e8732aaff6f21d048c8677823fc04`.

Current source provides:

- structured differential output with clinical summary, red flags, recommended workup and suggested referrals;
- structured SOAP `S/O/A/P` generation;
- explicit anti-hallucination/source constraints in the prompts;
- explicit rule that Plan is suggestion/draft direction only and must not contain directly executable medication/treatment orders;
- production-oriented auth/quota/kill-switch code on default branch, but the current P0 #6 finding establishes that Cloudflare Access assertions are not yet cryptographically verified on default;
- current open research for specialty-scoped validation (#4) and candidate/revision lifecycle (#7).

### Existing work still outranks new product breadth

The Product Board's sequencing remains stronger than the new market signals:

1. #6 P0 authentication boundary must be correctly fixed and runtime-sensitive claims remain unverified until an appropriate deployed/prod-equivalent path is exercised.
2. #10 P2 release/regression gate must actually execute the security suite and provider canary success must not mean zero provider calls.
3. #4/#7 may continue only as bounded research/validation after trust/release gates; active PRs already exist.
4. Real clinical deployment, EHR write-back, autonomous coding/diagnosis and revenue-cycle workflows remain explicitly outside current owner-approved scope.

Historical issue wording such as `P1 Research` or heuristic `92/100` in #4/#7 is not reinterpreted as proven P1 product severity. Under Issue Quality v2 those are research/decision-priority signals; `severity` for an unvalidated opportunity remains `NOT_ESTABLISHED` unless the severity rubric is independently met.

---

## Opportunity Map — `clinical-scribe-worker`

| Category | Decision | Evidence / reasoning |
|---|---|---|
| **MUST MATCH** | Authentication and reviewer identity must be cryptographically trustworthy and fail closed | Existing #6 P0; active PRs; current highest-risk product truth |
| **MUST MATCH** | A requested verification/canary must prove it actually executed the declared path | Existing #10; green-with-zero-execution is not evidence |
| **MUST MATCH** | Generated/refined clinical content remains a candidate until explicit human review; source support must remain inspectable | Dragon current diagnosis-specificity flow + existing #4/#7 |
| **SHOULD BE BETTER** | Derived artifacts should expose source/support discrepancies before irreversible downstream use | Abridge pre-bill strategy; reuse only as a validation principle in current scope |
| **SHOULD BE BETTER** | Release evidence should be versioned by model/prompt/parser/workflow rather than collapsed into one aggregate score | UK lifecycle-assurance signal + #4 |
| **DIFFERENTIATOR** | Synthetic-first, source-aware, fail-closed evidence boundaries instead of premature clinical breadth | Owner-approved current direction |
| **ADJACENT IDEA** | If a future authorized synthetic workflow derives another structured artifact from the note, test one evidence-linked candidate/review fixture before adding infrastructure | smallest transferable Abridge pattern |
| **DO NOT COPY** | CDI/revenue-cycle platform, claim submission, EHR write-back, autonomous diagnosis/coding, real-patient context store, compliance dashboard | outside owner scope and no current job evidence |
| **DO NOT COPY** | generic provenance ledger / policy engine / clinical workflow framework solely because competitors broaden their platforms | architecture before value evidence; #4/#7 already provide bounded contracts |

---

## Four-Gate Review

### Candidate A — evidence-linked downstream discrepancy review

Proposed fingerprint if it ever becomes actionable:

`clinical-scribe-worker + owner-authorized derived structured artifact + reviewer must manually compare derived claims to source note/transcript + existing #4/#7 receipts cannot express support/discrepancy + bounded synthetic fixture demonstrates avoidable review error or repeated manual cross-check`

#### 1. Problem / value

Abridge demonstrates a real market job: downstream structured artifacts can drift from what source documentation supports, and reviewers benefit from evidence surfaced before external submission. But this repo has **no supported CDI/billing/claim workflow** and no authorized downstream artifact whose manual reconciliation is failing. Existing #4/#7 already cover the smaller source-support/candidate primitives.

**Gate result:** market pattern exists; current local problem/value is **not established**.

#### 2. Priority

```yaml
kind: OPPORTUNITY
severity: NOT_ESTABLISHED
decision_priority: LOW
evidence: NEEDS_EVIDENCE
triage: NEEDS_EVIDENCE
auto_implementation: false
runtime_verification: NEEDS_RUNTIME_VERIFICATION
```

It is not P2/P1 because a competitor moved downstream. No supported current user completion, recovery or maintenance failure has been demonstrated.

#### 3. Minimum solution

Do nothing in product code now. If owner later authorizes a new **synthetic** derived artifact, first add a single controlled fixture that:

1. freezes the source note/transcript revision;
2. derives one structured candidate;
3. shows exact supporting/unsupported source references;
4. requires explicit accept/reject;
5. records a receipt and fails stale/unknown support closed.

Only if this bounded fixture cannot be represented by #4/#7 should a new schema be considered. No billing service, code registry, new database, generic lineage graph or EHR connector is the minimum solution.

#### 4. Research / implementation separation

No Issue is created. No BUILD decision exists. `BUILD` in a future experiment would only support a later scoped decision; it would not authorize billing/coding/EHR implementation.

**Decision: HOLD / CENTRAL REPORT ONLY.**

### Candidate B — diagnosis-specificity candidate workflow

#### Gate 1

Dragon provides first-party confirmation that diagnosis refinement can be useful while remaining rationale-backed and explicitly user-controlled.

#### Gate 2

Current repo #7 already owns candidate review/revision behavior; no distinct current user failure is established.

#### Gate 3

Minimum is to reuse #7's existing candidate/diff/accept/reject/stale-input contract if this research ever touches Assessment refinement. Do not add a separate diagnosis suggestion service/state machine.

#### Gate 4

#7 has active PR #9. This signal is therefore **DEDUPED / SKIPPED_LOCKED** and is retained in the central report only. No comment or lock marker was needed because no Issue state was modified.

### Candidate C — lifecycle assurance / patient-information layer

The UK recommendation package and VA deployment pattern are strategically relevant only if intended use changes. Current supported scope is synthetic/non-clinical and explicitly forbids real patient/PII use.

```yaml
kind: RESEARCH
severity: NOT_ESTABLISHED
decision_priority: DEFERRED_UNTIL_SCOPE_CHANGE
triage: NEEDS_EVIDENCE
auto_implementation: false
```

**Decision:** no current Issue. A missing consent/compliance subsystem is not a defect for a product that does not support a real-patient workflow.

---

## Adjacent Ideas

1. **Source-linked derived-artifact fixture, not a platform:** if a later authorized synthetic workflow creates codes/referral/other structured content, first test whether existing source spans + revision receipt can expose support/unknowns.
2. **Explicit effect boundary:** keep `suggest`, `accept into note`, and `sync/write externally` as different states. This is a design principle, not permission to add EHR actions.
3. **Lifecycle evidence as release metadata:** if #4 progresses, retain exact model/prompt/parser/pack version and `PROMOTE/BLOCK/NEEDS_REVIEW`; do not compress safety-critical regressions into an aggregate score.

## Cross-portfolio ideas

No new shared component passes the cross-project creation gate this round. Two reusable principles are worth retaining only when a concrete repository has a validated job:

- **derived output must remain traceable to source evidence and review state;**
- **proposal authority, canonical mutation authority and external-effect authority are separate.**

These principles already recur across several Reese-max products, but recurring architecture vocabulary is not evidence that a generic provenance/permission framework should be built.

## Rejected / deferred ideas

- **Build CDI/coding/revenue-cycle workflow because Abridge added pre-bill review:** rejected; wrong product scope and no local user evidence.
- **Add autonomous ICD/CPT/DRG suggestions to the current prototype:** rejected; owner direction explicitly places autonomous diagnosis/coding outside current scope, and #7 already supplies the safer candidate-review primitive.
- **Add EHR sync because Dragon separates note update from EHR sync:** rejected; the useful lesson is the boundary, not the integration.
- **Create consent/notice database now:** rejected; no authorized real-patient workflow. Preserve this as a future intended-use requirement, not current engineering scope.
- **Create a healthcare-AI compliance engine from the UK recommendations:** rejected; recommendations are system-level policy input, not evidence this prototype needs a compliance product.
- **Create a generic evidence lineage graph:** rejected; #4/#7 are the smaller bounded contracts and no current fixture proves them insufficient.
- **Treat Abridge/Suki/Dragon vendor claims as independent clinical efficacy evidence:** rejected. Vendor releases are product-strategy evidence only.
- **Treat #4/#7 historical `P1 Research` wording or heuristic scores as P1 defect severity:** rejected under Issue Quality v2.

---

## Issue Mapping / duplicate / coordination check

| Signal / fingerprint | Existing mapping | Decision |
|---|---|---|
| Cloudflare Access assertion trust | #6 / PRs #15/#13/#8 | active security scope; untouched |
| CI/security suite actually executes; provider canary cannot succeed with zero calls | #10 / PRs #14/#11 | active release-evidence scope; untouched |
| specialty/workflow omission, unsupported-addition, attribution/negation validation | #4 / PRs #12/#5 | Abridge/MHRA source-evidence/lifecycle signal maps here conceptually; `SKIPPED_LOCKED`, no comment |
| candidate section repair, diff, stale input, explicit Accept/Reject, revision receipt | #7 / PR #9 | Dragon candidate-action signal maps here; `SKIPPED_LOCKED`, no comment |
| CDI/billing/claim reconciliation | none | outside approved product scope; no Issue |
| real-patient consent/notice/opt-out | none | deferred until owner explicitly changes intended use; no Issue |

No Issue lock was acquired because no Issue, PR or shared mutable tracking state was changed. A unique append-only radar file was used instead. No owner rejection was reopened.

---

## Sources

### Public web — primary intelligence source, checked 2026-09-21

1. Abridge — **2026-09-14** — pre-bill review for CDI/coding teams: https://www.abridge.com/press-release/pre-bill-review-for-cdi-and-coding-teams — `CONFIRMED` first-party strategy/capability signal.
2. Microsoft Dragon Copilot — publication date not exposed; checked **2026-09-21** — diagnosis specificity suggestions: https://support.microsoft.com/en-us/dragon-copilot/physicians/current/diagnosis-specificity-suggestions — `CONFIRMED_CURRENT` first-party capability.
3. UK Government / MHRA — **2026-09-10** — National Commission AI-in-healthcare recommendations: https://www.gov.uk/government/news/independent-commission-led-by-nhs-doctors-sets-out-blueprint-to-accelerate-safe-ai-adoption-in-healthcare — `CONFIRMED` government recommendation/strategy signal.
4. UK Government / MHRA — **2026-09-10** — full recommendation landing page: https://www.gov.uk/government/publications/national-commission-into-the-regulation-of-ai-in-healthcare-recommendations-for-a-future-regulatory-framework — `CONFIRMED`; cross-government response pending.
5. VA Orlando — **2026-01-27** — ambient-scribe transparency/decline pattern: https://www.va.gov/orlando-health-care/news-releases/orlando-va-health-care-system-to-implement-ambient-scribe-technology-to-enhance-veteran-care/ — `CONFIRMED`, older representative deployment pattern only.
6. VA Minneapolis — **2026-04-27** — patient permission/opt-out + clinician review: https://www.va.gov/minneapolis-health-care/stories/minneapolis-va-healthcare-system-introduces-new-ai-technology-to-improve-veterans-primary-care-experience/ — `CONFIRMED`, older representative deployment pattern only.

External claims were not converted into this product's efficacy, incidence or ROI claims.

### GitHub — product truth, direction, dedupe and coordination only

- `Reese-max/autodev-ng/docs/portfolio-audit/2026-09-14-issue-quality-v2.md` @ blob `8167e10798071d2276addaff6b201c6b0e904a2a`.
- `Reese-max/autodev-ng/docs/portfolio-audit/2026-09-18T1100Z-product-board-delta.md`.
- `Reese-max/autodev-ng/docs/competitive-intelligence/2026-09-18T100114Z-external-radar.md`.
- `Reese-max/autodev-ng/docs/competitive-intelligence/2026-09-19T175958Z-external-radar.md`.
- `Reese-max/clinical-scribe-worker` current `README.md`, `AGENTS.md`, `src/scribe.ts`, `public/scribe.html`, Issues #4/#6/#7/#10, and all-state/open PR surface.

---

## What Changed

1. Fresh inventory is now **42 owned / 41 unarchived**, fully paginated; older 41/40 snapshots are not used as the universe.
2. Focal default branch has **no new product-code change** since the prior clinical-scribe radar; HEAD remains `4de4e7e...` and product/security baseline remains `88bb746...`.
3. Newly retained external signal for this round: Abridge's 2026-09-14 pre-bill review shows clinical-AI vendors carrying source evidence into downstream discrepancy review before an external effect.
4. Dragon's current diagnosis-specificity workflow confirms a safer boundary already represented by #7: rationale-backed candidate, explicit accept/reject, no silent canonical mutation, separate external sync.
5. UK 2026-09-10 recommendations strengthen lifecycle/human-oversight evidence requirements but do not alter this prototype's current intended-use scope.
6. These signals **do not overturn** owner direction. They reinforce `trust/release evidence first -> bounded source-aware validation/revision -> only then consider broader intended use`.
7. Historical `P1 Research`/high-score language in #4/#7 remains research-priority language, not independently proven P1 severity.
8. New Issues: **0**. Existing Issue/PR comments or edits: **0**. Implementation authorizations: **0**. Runtime validations: **0**.

## Completion / gaps / fair cursor

- External direct/adjacent/policy exploration completed with first-party vendor and government sources. A fresh community search did not produce a stronger decision-grade signal and no anecdote was promoted.
- Current default-branch truth, current Product Board direction, historical clinical radars, Issues and all-state/open PRs were checked.
- No live provider, deployed auth boundary, patient/clinician workflow or production-equivalent runtime was exercised. Runtime-sensitive items remain `NEEDS_RUNTIME_VERIFICATION` as applicable.
- This radar does **not** declare the repository or portfolio CLEAN.
- Notification threshold: **not met**. Abridge's downstream strategy is meaningful market context, but it does not create a high-value current opportunity, a validated cross-project component, or evidence that overturns the owner-approved synthetic/non-clinical direction. Dragon/MHRA signals confirm already-tracked boundaries.
- Next fair-rotation cursor: **`Reese-max/MaterialYouNewTab`**.
